Fexofenadine Hydrochloride
Phase 2Small molecule
Fexofenadine Hydrochloride is one of 27 small molecule programs targeting ST-segment Elevation Myocardial Infarction (STEMI). It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in AIN
#DrugCompanyPhaseTrials
1Reblozyl
Bristol-Myers SquibbPhase 2
Jevtana
SanofiPhase 2
Lynparza
AstraZenecaPhase 2
Avastin
RochePhase 2
Plaquenil
Jazz PharmaceuticalsPhase 2
GM-CSF
YY-mAbs Therapeutics
Phase 3
Paraplatin
AAvyxa
Phase 2
Brukinsa
BBeOne Medicines
Phase 2
Vepesid
AAvyxa
Phase 2
Rayos
RRoxane Laboratories
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Oral1 trial
Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition
Completed·—·Phase 1·NCT01888718·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fexofenadine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Ghent